<DOC>
	<DOCNO>NCT02313545</DOCNO>
	<brief_summary>In open label study , 50 eligible woman assign receive investigational product ( IZN-6NVS ) - 2.5 g cream/day 14 day , follow 3 application per week next 4 week . Clinical assessment severity vaginitis perform baseline 2 6 week treatment . The study evaluate safety , tolerability efficacy IZN-6NVS vaginal cream , treatment atrophic vaginitis ( AV ) desquamative inflammatory vaginitis ( DIV ) .</brief_summary>
	<brief_title>Phase I-B Study Evaluate Safety , Tolerability Efficacy IZN-6NVS Treatment AV DIV</brief_title>
	<detailed_description>This Phase IB study comprise three study group : - Group 1 : Women naturally surgically menopausal symptomatic AV , decline treatment topical systemic estrogen . - Group 2 : Women render menopausal result pharmacologic treatment ( include , limited , aromatase inhibitor treatment , selective estrogen receptor modifier ( SERMs ) , GnRH analog treatment ) , decline treatment topical systemic estrogen . - Group 3 : Pre-menopausal woman diagnose DIV . The study evaluate safety , tolerability efficacy IZN-6NVS vaginal cream , treatment atrophic vaginitis ( AV ) desquamative inflammatory vaginitis ( DIV ) . 20 eligible woman group 1 2 10 eligible woman group 3 assign receive 2.5 g cream/day first 14 day , follow 3 application per week next 4 week . Clinical assessment severity vaginitis perform baseline 2 6 week treatment , end study . Patient report symptom severity assess questionnaire baseline 2 6 week treatment , follow-up .</detailed_description>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Atrophic Vaginitis</mesh_term>
	<criteria>1 . Women age 18 2 . For group 1 2 : I. Selfreported amenorrhea least 12 month documentation menopause base serum E2 ≤ 150 pg/ml . II . Selfreporting least one moderate severe symptom vaginal atrophy 4point scale ( 0=none ; 1=mild ; 2=moderate ; 3=severe ) : Vaginal dryness Vaginal discomfort irritation Vaginal itch Vaginal pain associate sexual activity Vaginal discharge Vaginal Malodor III . Clinical impression atrophy base examination vaginal cytological smear . IV . Vaginal pH &gt; 4.5 V. Endometrial thickness ≤5 mm determine US , abnormality note . 3 . For group 3 ( DIV ) : Clinical diagnosis DIV premenopausal woman without estrogen deficiency . 4 . For group : I . Willing comply use intravaginal cream contain S. nigra , C. asiatica , E. purpurea extract . II . Normal PAP smear within last 3 year . III . Able provide inform consent . 1 . Subjects recruit group 1 actively treat breast , uterine ovarian cancer within past year . 2 . Vaginal bleed unknown cause within 60 day enrollment 3 . Vaginal infection require treatment within 30 day enrollment 4 . Any known allergy plant extract study cream 5 . Any serious disease ; concomitant steroid use sex hormone treatment 6 . Endometrial thickness &gt; 5 mm measure ultrasound woman enrol diagnosis atrophic vaginitis 7 . Use vaginal moisturizer ( e.g . Replens , Gynomonal ) within 30 day enrollment . 8 . In group 1 2 , Use oral , transdermal , vaginal , systemic estrogen estrogen/progestin product within 30 day enrollment . 9 . Current urinary tract infection ( UTI ) ( clinical complaint UTI dipstick urinalysis positive nitrate blood ) 10 . History venous thromboembolic disease . 11 . Use another investigational agent within 12 week screen . 12 . Any medical psychiatric condition , investigator 's opinion , would preclude subject comply study protocol , include completion questionnaire . 13 . Subjects DIV pregnant try become pregnant include study . Similarly , subject DIV become pregnant study , patient remove study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>